神经精神治疗市场：按疾病、药物类别、给药途径、剂型、患者年龄层、医疗机构、医疗服务提供者类型、分销管道、支付方式和地区划分

预计到 2025 年，神经精神治疗市场规模将达到 762.1 亿美元，到 2032 年将达到 1,016.4 亿美元，2025 年至 2032 年的复合年增长率为 4.2%。

全球神经精神治疗市场在更广泛的医疗保健领域中占据着重要地位，涵盖了影响神经和精神功能的复杂疾病的治疗性介入。

神经精神疾病涵盖范围广泛，包括忧郁症、焦虑症、躁郁症、思觉失调症、注意力不足过动症（ADHD）、泛自闭症障碍以及阿兹海默症和帕金森氏症等神经退化性疾病。这些疾病对患者的认知、情绪和行为有显着影响，并给全球医疗保健带来沉重负担。

治疗市场涵盖多种治疗方法，包括药物疗法、心理疗法、神经刺激技术以及新兴创新治疗方法，例如数位疗法和精准医疗。由于人口老化、生活方式改变、压力增加以及诊断能力提高等因素，全球神经精神疾病的盛行率不断上升，从而推动了对有效治疗方案的需求。

鑑于这些疾病对经济和社会的重大影响，世界各地的医疗卫生系统正在增加对新治疗方法研发的投入。市场以持续创新为特征，製药、生技和医疗设备公司正积极开发下一代治疗方法，以期提高疗效、减少副作用并提供个人化治疗通讯协定，从而应对神经精神疾病的复杂性和多样性。

市场动态

全球神经精神疾病治疗市场受多种关键因素驱动，这些因素正在从根本上改变治疗格局。其中一个关键驱动因素是全球神经精神疾病盛行率的不断上升。根据世界卫生组织（世卫组织）报告，全球有超过9.7亿人患有精神疾病，而随着人口老化，神经退化性疾病也持续上升。

人们对心理健康的认识不断提高，对心理健康的歧视也逐渐减少，这提高了诊断率和就医意愿，显着扩大了患者群体。药物研发技术的进步，包括人工智慧辅助的监测、生物标记识别和个人化医疗方法，正在加速开发更具针对性和更有效的治疗方法。

政府措施和增加对精神卫生服务的医疗保健支出，尤其是在疫情之后，创造了有利的法规环境和资金筹措机会。然而，市场面临许多限制因素，包括高成本和漫长的核准流程（可能耗时10-15年，耗资数十亿美元）。由于神经精神药物的作用机制复杂且可能存在副作用，因此受到严格的监管要求，这进一步阻碍了其市场准入。这些疾病的异质性使得治疗标准化变得困难，而治疗抗药性、用药依从性以及对复杂脑机制缺乏了解等挑战，仍然阻碍着相关领域的进展。

儘管面临诸多挑战，新兴市场仍蕴藏着巨大的机会，这得益于医疗基础建设的完善和心理健康意识提升的提升。数位疗法、远端医疗和人工智慧诊断工具的融合，为市场拓展开闢了新的途径。对早期疗育、预防性护理和联合治疗的日益重视，预示着市场成长的潜力；同时，新型药物递送系统和针对难治性疾病的突破性治疗方法的研发，也为那些能够满足这些关键未满足需求的创新型企业带来了巨大的商业性机会。

本报告的主要特点

• 本报告对全球神经精神治疗市场进行了详细分析，并给出了预测期（2025-2032 年）的市场规模和复合年增长率，以 2024 年为基准年。
• 它还重点介绍了各个细分市场的潜在商机，并描述了该市场中一系列有吸引力的投资提案。
• 它还提供了有关市场驱动因素、限制因素和机会、新产品发布和核准、市场趋势、区域展望以及主要企业采取的竞争策略的关键见解。
• 根据公司概况、产品系列、主要亮点、财务表现和策略等参数，对全球神经精神治疗市场的主要企业进行了分析。
• 本报告提供的见解将使负责人和公司经营团队能够就未来的产品发布、产品更新、市场扩张和行销策略做出明智的决策。
• 《全球神经精神疾病治疗市场》报告面向该行业的各类相关人员，例如投资者、供应商、产品製造商、经销商、新进业者和金融分析师。
• 相关人员可以透过各种策略矩阵更轻鬆地分析全球神经精神疾病治疗市场，从而做出决策。

目录

第一章 分析目标和先决条件

• 分析目的
• 先决条件
• 简称

第二章 市场展望

• 报告说明
  • 市场定义和范围
• 执行摘要

第三章：市场动态、监理及趋势分析

• 市场动态
• 司机
• 抑制因素
• 机会
• 影响分析
• 重大进展
• 监管情景
• 产品发布/核准
• PEST分析
• 波特五力分析
• 企业合併情景
• 产业趋势

第四章 全球神经精神疾病治疗市场（依疾病区分）（2020-2032 年）

• 重度忧郁症
• 躁郁症
• 焦虑症
• 频谱思觉失调症
• 创伤和压力相关疾病
• 强迫症及相关障碍
• 注意力不足过动症
• 泛自闭症障碍
• 物质使用障碍
• 睡眠/觉醒障碍
• 神经认知障碍
• 伴随精神症状的运动障碍
• 饮食障碍
• 人格障碍

5. 全球神经精神疾病治疗市场（依药物类别划分）（2020-2032 年）

• 抗忧郁症
• 抗精神病药物
• 情绪稳定剂
• 抗焦虑药物、镇静催眠药
• 过动症药物
• 认知增强剂
• 用于治疗物质使用疾患的药物
• 运动和衝动控制药物
• 辅助症状控制药物

6. 全球神经精神药物市场依给药途径划分（2020-2032 年）

• 口服
• 肠外
• 鼻腔
• 经皮
• 舌下/颊部给药

7. 全球神经精神疾病治疗市场（依分子类型划分）（2020-2032 年）

• 低分子化合物
• 生技药品
• 组合药物（固定剂量组合药物）

8. 全球神经精神药物市场按剂型类型划分（2020-2032 年）

• 速释製剂
• 缓释性/控释
• 长效缓释製剂
• 口腔崩坏製剂
• 口服液体製剂
• 前驱药物製剂

9. 全球神经精神疾病治疗市场（依病患年龄层划分）（2020-2032 年）

• 儿童
• 青年
• 成年人和老年人

第十章 全球神经精神治疗市场（依医疗机构划分）（2020-2032 年）

• 住院治疗
• 门诊
• 社区医学
• 居家医疗
• 远端医疗，虚拟护理

第十一章 全球神经精神治疗市场（按医疗服务提供者类型划分）（2020-2032 年）

• 精神科医生
• 神经科
• 家庭医生
• 心理师和治疗师
• 成瘾专家
• 综合医疗团队

第十二章 全球神经精神疾病治疗市场依通路划分（2020-2032 年）

• 医院药房
• 零售药房
• 网路药房

第十三章 全球神经精神治疗市场以支付方式划分（2020-2032 年）

• 民众
• 私人的

第十四章 全球神经精神疾病治疗市场（按地区划分）（2020-2032 年）

• 北美洲
  • 美国
  • 加拿大
• 拉丁美洲
  • 巴西
  • 阿根廷
  • 墨西哥
  • 其他拉丁美洲
• 欧洲
  • 德国
  • 英国
  • 西班牙
  • 法国
  • 义大利
  • 俄罗斯
  • 其他欧洲
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • ASEAN
  • 其他亚太地区
• 中东
  • 海湾合作委员会国家
  • 以色列
  • 其他中东地区
• 非洲
  • 南非
  • 北非
  • 中非

第十五章 竞争格局

• Johnson and Johnson
• Pfizer Inc
• Roche Holding AG
• Novartis AG
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Otsuka Holdings Co Ltd
• Lundbeck A/S
• AbbVie Inc（including Allergan）
• Biogen Inc
• Teva Pharmaceutical Industries Ltd
• Janssen Pharmaceutical Companies

第十六章 分析师建议

• 机会
• 分析师观点
• Coherent Opportunity Map (COM)

第十七章 参考文献与分析方法

• 参考
• 分析方法
• 关于 Coherent Market Insights

Neuropsychiatric Disorders Treatment Market is estimated to be valued at USD 76.21 Bn in 2025 and is expected to reach USD 101.64 Bn by 2032, growing at a compound annual growth rate (CAGR) of 4.2% from 2025 to 2032.

The global neuropsychiatric disorders treatment market represents a critical segment within the broader healthcare landscape, encompassing therapeutic interventions for complex conditions that affect both neurological and psychiatric functions.

Neuropsychiatric disorders include a diverse range of conditions such as depression, anxiety, bipolar disorder, schizophrenia, attention deficit hyperactivity disorder (ADHD), autism spectrum disorders, and neurodegenerative diseases like Alzheimer's and Parkinson's disease. These conditions significantly impact patients' cognitive, emotional, and behavioral functioning, creating substantial healthcare burdens worldwide.

The treatment market encompasses various therapeutic modalities including pharmacological interventions, psychotherapy, neurostimulation techniques, and emerging innovative therapies such as digital therapeutics and precision medicine approaches. The increasing prevalence of neuropsychiatric disorders globally, driven by factors such as aging populations, lifestyle changes, increased stress levels, and improved diagnostic capabilities, has intensified the demand for effective treatment solutions.

Healthcare systems worldwide are recognizing the substantial economic and social impact of these conditions, leading to increased investment in research and development of novel therapeutic approaches. The market is characterized by continuous innovation, with pharmaceutical companies, biotechnology firms, and medical device manufacturers actively developing next-generation treatments that promise improved efficacy, reduced side effects, and personalized treatment protocols to address the complex and heterogeneous nature of neuropsychiatric disorders.

Market Dynamics

The global neuropsychiatric disorders treatment market is propelled by several key drivers that are fundamentally reshaping the therapeutic landscape. The primary driver is the escalating global prevalence of neuropsychiatric conditions, with the World Health Organization reporting that mental health disorders affect over 970 million people worldwide, while neurodegenerative diseases continue to rise with aging populations.

Increased awareness and reduced stigma surrounding mental health have led to higher diagnosis rates and treatment-seeking behavior, substantially expanding the patient pool. Technological advancements in drug discovery, including artificial intelligence-driven research, biomarker identification, and personalized medicine approaches, are accelerating the development of more targeted and effective therapies.

Government initiatives and increased healthcare spending on mental health services, particularly post-pandemic, have created favorable regulatory environments and funding opportunities. However, the market faces significant restraints including the high cost of drug development and lengthy approval processes, which can span 10-15 years and cost billions of dollars. Stringent regulatory requirements for neuropsychiatric medications, given their complex mechanisms and potential side effects, create additional barriers to market entry. The heterogeneous nature of these disorders makes treatment standardization challenging, while issues such as treatment resistance, medication adherence, and limited understanding of complex brain mechanisms continue to impede progress.

Despite these challenges, substantial opportunities exist in emerging markets with improving healthcare infrastructure and increasing mental health awareness. The integration of digital therapeutics, telemedicine, and AI-powered diagnostic tools presents new avenues for market expansion. Growing focus on early intervention, preventive care, and combination therapies offers potential for market growth, while the development of novel drug delivery systems and breakthrough therapies for treatment-resistant conditions represents significant commercial opportunities for innovative companies positioned to address these critical unmet medical needs.

Key Features of the Study

• This report provides in-depth analysis of the global neuropsychiatric disorders treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global neuropsychiatric disorders treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Johnson and Johnson, Pfizer Inc, Roche Holding AG, Novartis AG, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Otsuka Holdings Co Ltd, H. Lundbeck A/S, AbbVie Inc (including Allergan), Biogen Inc, Teva Pharmaceutical Industries Ltd, and Janssen Pharmaceutical Companies
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global neuropsychiatric disorders treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global neuropsychiatric disorders treatment market

Market Segmentation

• Disorder Insights (Revenue, USD Bn, 2020 - 2032)
  • Major Depressive Disorder
  • Bipolar Disorder
  • Anxiety Disorders
  • Schizophrenia Spectrum Disorders
  • Trauma- and Stressor-Related Disorders
  • Obsessive-Compulsive and Related Disorders
  • Attention-Deficit/Hyperactivity Disorder
  • Autism Spectrum Disorder
  • Substance Use Disorders
  • Sleep-Wake Disorders
  • Neurocognitive Disorders
  • Movement Disorders with psychiatric symptom control
  • Eating Disorders
  • Personality Disorders
• Drug Class Insights (Revenue, USD Bn, 2020 - 2032)
  • Antidepressants
  • Antipsychotics
  • Mood Stabilizers
  • Anxiolytics and Sedative-Hypnotics
  • ADHD Medications
  • Cognitive Enhancers
  • Substance Use Disorder Medications
  • Movement and Impulse Control Agents
  • Adjunctive Symptom-Control Agents
• Route of Administration Insights (Revenue, USD Bn, 2020 - 2032)
  • Oral
  • Parenteral
  • Intranasal
  • Transdermal
  • Sublingual or Buccal
• Molecule Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Small molecules
  • Biologics
  • Combination drugs (fixed-dose combinations)
• Formulation Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Immediate release
  • Extended release or controlled release
  • Long-acting depot formulations
  • Orally disintegrating formulations
  • Liquid oral formulations
  • Prodrug formulations
• Patient Age Group Insights (Revenue, USD Bn, 2020 - 2032)
  • Pediatric
  • Adolescent
  • Adult/Geriatric
• Care Setting Insights (Revenue, USD Bn, 2020 - 2032)
  • Inpatient
  • Outpatient
  • Community-based Care
  • Home-based Care
  • Telehealth and Virtual Care
• Provider Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Psychiatrists
  • Neurologists
  • Primary Care Physicians
  • Psychologists and Therapists
  • Addiction Medicine Specialists
  • Integrated Care Teams
• Distribution Channel Insights (Revenue, USD Bn, 2020 - 2032)
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Payment Type Insights (Revenue, USD Bn, 2020 - 2032)
  • Public
  • Private
• Regional Insights (Revenue, USD Bn, 2020 - 2032)
  • North America
  • U.S.
  • Canada
  • Latin America
  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America
  • Europe
  • Germany
  • U.K.
  • Spain
  • France
  • Italy
  • Russia
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
  • GCC Countries
  • Israel
  • Rest of Middle East
  • Africa
  • South Africa
  • North Africa
  • Central Africa
• Key Players Insights
  • Johnson and Johnson
  • Pfizer Inc
  • Roche Holding AG
  • Novartis AG
  • Eli Lilly and Company
  • Bristol-Myers Squibb Company
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Takeda Pharmaceutical Company Limited
  • Otsuka Holdings Co Ltd
  • Lundbeck A/S
  • AbbVie Inc (including Allergan)
  • Biogen Inc
  • Teva Pharmaceutical Industries Ltd
  • Janssen Pharmaceutical Companies

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Global Neuropsychiatric Disorders Treatment Market, By Disorder
  • Global Neuropsychiatric Disorders Treatment Market, By Drug Class
  • Global Neuropsychiatric Disorders Treatment Market, By Route of Administration
  • Global Neuropsychiatric Disorders Treatment Market, By Molecule Type
  • Global Neuropsychiatric Disorders Treatment Market, By Formulation Type
  • Global Neuropsychiatric Disorders Treatment Market, By Patient Age Group
  • Global Neuropsychiatric Disorders Treatment Market, By Care Setting
  • Global Neuropsychiatric Disorders Treatment Market, By Provider Type
  • Global Neuropsychiatric Disorders Treatment Market, By Distribution Channel
  • Global Neuropsychiatric Disorders Treatment Market, By Payment Type
  • Global Neuropsychiatric Disorders Treatment Market, By Region

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
• Driver
• Restraint
• Opportunity
• Impact Analysis
• Key Developments
• Regulatory Scenario
• Product Launches/Approvals
• PEST Analysis
• PORTER's Analysis
• Merger and Acquisition Scenario
• Industry Trends

4. Global Neuropsychiatric Disorders Treatment Market, By Disorder, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Major Depressive Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Bipolar Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Anxiety Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Schizophrenia Spectrum Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Trauma- and Stressor-Related Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Obsessive-Compulsive and Related Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Attention-Deficit/Hyperactivity Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Autism Spectrum Disorder
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Substance Use Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Sleep-Wake Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neurocognitive Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Movement Disorders with psychiatric symptom control
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Eating Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Personality Disorders
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

5. Global Neuropsychiatric Disorders Treatment Market, By Drug Class, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Antidepressants
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Antipsychotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Mood Stabilizers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Anxiolytics and Sedative-Hypnotics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• ADHD Medications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Cognitive Enhancers
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Substance Use Disorder Medications
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Movement and Impulse Control Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Adjunctive Symptom-Control Agents
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

6. Global Neuropsychiatric Disorders Treatment Market, By Route of Administration, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Oral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Parenteral
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Intranasal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Transdermal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Sublingual or Buccal
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

7. Global Neuropsychiatric Disorders Treatment Market, By Molecule Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Small molecules
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Biologics
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Combination drugs (fixed-dose combinations)
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

8. Global Neuropsychiatric Disorders Treatment Market, By Formulation Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Immediate release
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Extended release or controlled release
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Long-acting depot formulations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Orally disintegrating formulations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Liquid oral formulations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Prodrug formulations
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

9. Global Neuropsychiatric Disorders Treatment Market, By Patient Age Group, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Pediatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Adolescent
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Adult/Geriatric
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

10. Global Neuropsychiatric Disorders Treatment Market, By Care Setting, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Inpatient
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Outpatient
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Community-based Care
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Home-based Care
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Telehealth and Virtual Care
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

11. Global Neuropsychiatric Disorders Treatment Market, By Provider Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Psychiatrists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Neurologists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Primary Care Physicians
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Psychologists and Therapists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Addiction Medicine Specialists
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Integrated Care Teams
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

12. Global Neuropsychiatric Disorders Treatment Market, By Distribution Channel, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Hospital Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Retail Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Online Pharmacies
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

13. Global Neuropsychiatric Disorders Treatment Market, By Payment Type, 2020-2032, (USD Bn)

• Introduction
  • Market Share Analysis, 2025 and 2032 (%)
  • Y-o-Y Growth Analysis, 2021 - 2032
  • Segment Trends
• Public
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)
• Private
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD Bn)

14. Global Neuropsychiatric Disorders Treatment Market, By Region, 2020 - 2032, Value (USD Bn)

• Introduction
  • Market Share (%) Analysis, 2025, 2028 & 2032, Value (USD Bn)
  • Market Y-o-Y Growth Analysis (%), 2021 - 2032, Value (USD Bn)
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • U.S.
    • Canada
• Latin America
  • Introduction
  • Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country, 2020 - 2032, Value (USD Bn)
    • GCC Countries
    • Israel
    • Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, By Disorder, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Drug Class, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Route of Administration, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Molecule Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Formulation Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Patient Age Group, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Care Setting, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Provider Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Distribution Channel, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Payment Type, 2020 - 2032, Value (USD Bn)
  • Market Size and Forecast, By Country/Region, 2020 - 2032, Value (USD Bn)
    • South Africa
    • North Africa
    • Central Africa

15. Competitive Landscape

• Johnson and Johnson
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Pfizer Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Roche Holding AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Novartis AG
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Eli Lilly and Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Bristol-Myers Squibb Company
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AstraZeneca PLC
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• GlaxoSmithKline plc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Takeda Pharmaceutical Company Limited
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Otsuka Holdings Co Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Lundbeck A/S
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• AbbVie Inc (including Allergan)
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Biogen Inc
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Teva Pharmaceutical Industries Ltd
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies
• Janssen Pharmaceutical Companies
  • Company Highlights
  • Product Portfolio
  • Key Developments
  • Financial Performance
  • Strategies

16. Analyst Recommendations

• Wheel of Fortune
• Analyst View
• Coherent Opportunity Map

17. References and Research Methodology

• References
• Research Methodology
• About us